The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated×2•Originally published 18 February 2026•Updated 18 February 2026•

1 min read

Moderna Shares Jump 6.5% as FDA Sets August Deadline for mRNA-1010 Flu Vaccine

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Moderna Inc. shares jumped 6.5% to reach $47 following a regulatory breakthrough regarding its seasonal flu vaccine candidate, mRNA-1010. The U.S. Food and Drug Administration (FDA) reversed its previous refusal to review the vaccine after a successful "Type A" meeting between the company and regulators. This pivotal meeting resolved outstanding concerns, leading the FDA to establish a formal decision deadline for August 5. The reversal marks a critical strategic milestone for Moderna as it seeks to diversify its mRNA portfolio beyond COVID-19 products. Investors cheered the newfound clarity on the regulatory timeline, which significantly improves the prospects for commercialization and steady revenue streams. The company remains focused on leveraging its innovative technology to address a broader range of respiratory illnesses and expand its global market presence.

4 months ago

Version History

Version 24 months ago

What changed: Updated with the specific vaccine identifier (mRNA-1010), the Type A meeting details, the August 5 decision deadline, and the 6.5% stock price increase.

Version 14 months ago

What changed: Updated to reflect that the FDA's reversal followed concessions from Moderna and specified that the initial rejection occurred just one week prior.